Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Bakris, G.; Agarwal, R.; Anker, S.; Pitt, B.; Ruilope, L.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; Filippatos, G.; S Temelkova-Kurktschiev, Theodora

doi:10.1056/nejmoa2025845

Public

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Shared by NobleBlocks on Oct 23, 2020 • 12:00 AM UTC

Authors:

G. Bakris

R. Agarwal

S. Anker

Abstract

BACKGROUND Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. METHODS In this...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!